Kathryn R. Wagner, MD, PhD
Photo: Kathryn R. Wagner
Elected 2015

Dr. Wagner is Global Head of Neurscience, Translational Medicine at Novartis Institutes for Biomedical Research in Basel, Switzerland.  Previously, she was the Global Head of Neuromuscular Disorders at Roche Pharma where she advanced the approvals of risdiplam, the first oral drug for spinal muscular atrophy and delandistrogene moxeparvovec, the first gene therapy for Duchenne muscular dystrophy.  Prior to joining industry, she was the founding Director of the Center for Genetic Muscle Disorders at the Kennedy Krieger Institute and Professor of Neurology and Neuroscience at the Johns Hopkins School of Medicine. In these roles she was a thought leader in the multidisciplinary care of muscular dystrophy patients, the development of novel preclinical models of muscle disorders including xenograft models, and the understanding of the role of myostatin in muscle disease and repair.